Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus

Şazi İMAMOĞLU

doi:https://doi.org/10.46310/tjim.815794

Makale detayları

Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus

Yazarlar:

Şazi İMAMOĞLU

Yayıncı:

Nizameddin KOCA

Ana Başlıklar:

Hastalıklar

Dergi:

Turkish Journal of Internal Medicine 2021 Vol.3 Issue 1, pp.1-5

Belge Tipi:

Makale

Yayın Tarihi:

1/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000637827

Sıklık:

Üç Aylık

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.815794

Özet:

 

Type 2 diabetes is manifested by impaired insulin secretion in pancreatic beta cells, increased glucagon secretion in alpha cells, and generally has a history of insulin resistance. The treatment of glucose metabolism disorder and the resulting hyperglycemia constitute an important part of the treatment of type 2 diabetes. Glycemic targets can be targeted with A1C <7% to reduce the risk of micro and macrovascular complications in eligible patients, and A1C <6.5% to reduce the risk of diabetic chronic renal failure and retinopathy in those with low risk of hypoglycemia. We can consider the treatment of hyperglycemia in two components; lifestyle changes and glucose-lowering agent therapy.

Makale detayları

Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus

Yazarlar: Şazi İMAMOĞLU

Yayıncı: Nizameddin KOCA

Ana Başlıklar: Hastalıklar

Dergi: Turkish Journal of Internal Medicine 2021 Vol.3 Issue 1, pp.1-5

Belge Tipi: Makale

Yayın Tarihi: 1/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000637827

Sıklık: Üç Aylık

eISSN: 2687-4245

DOI: https://doi.org/10.46310/tjim.815794

Sayı

Yazarlar:

Şazi İMAMOĞLU

Yayıncı:

Nizameddin KOCA

Ana Başlıklar:

Hastalıklar

Dergi:

Turkish Journal of Internal Medicine 2021 Vol.3 Issue 1, pp.1-5

Belge Tipi:

Makale

Yayın Tarihi:

1/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000637827

Sıklık:

Üç Aylık

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.815794